• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
All
Options & Futures
Funds
IPO Subscription
Structured Products
Investment Wiki
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List

Nektar Therap(NKTR.US)

Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec16
HC Wainwright Raises Nektar Therapeutics Price Target to $135
18:16
Nektar Therapeutics' Drug Rezpegaldesleukin Fails to Meet Main Goal in Mid-Stage Study, Shares Fall
13:59
Nektar Therapeutics Announces Positive Phase 2b Results for Rezpegaldesleukin in Severe Alopecia Areata
12:31
Nov28
Citi initiates coverage of Nektar Therapeutics with a Buy rating and sets a $102 price target
13:02
Nov17
William Blair Maintains Hold Rating on NKTR
23:26
Nov11
H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics
12:02

Schedules & Filings

Schedules
Filings
Nov6
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 11.79 M, Net Income -35.52 M, EPS -1.8748

Aug7
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 11.18 M, Net Income -41.59 M, EPS -2.9525

Jun9
Reverse Stock Split(EST)

1-for-15 Reverse Stock Split

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
INBS
11.599
+182.90%
+7.490
ANGH
3.878
+67.17%
+1.560
ESHA
21.800
+51.60%
+7.440
ESHAR
0.2500
+47.06%
+0.080
NCL
0.2839
+46.34%
+0.088
ULY
3.740
+35.51%
+0.990
SIDU
3.510
+31.46%
+0.840
RDACR
0.2493
+31.21%
+0.059
DVLT
0.6686
+29.45%
+0.152
ORIS
1.565
+28.28%
+0.345
View More